TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07032038: First In Human, Multi-Center Open-Label Randomized Trial to Assess Safety of Rincell-1 Otic Neural Progenitor Cell-Based Therapy and Standard Care vs Standard Care Alone, in Adults With Neural Hearing Loss Eligible for C

Sponsor: Rinri Therapeutics · Phase: PHASE1/PHASE2 · Area: CNS_NEUROLOGY · Target Enrollment: 20 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$6,628,980

Rescue Site Savings

+$4,386,340

Unlock Full NCT07032038 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07032038 Rescue Dossier →